[Helicobacter pylori infection in patients with chronic hives and asthma].
Difficulties in treatment of allergic diseases (ADs) are often determined by the fact that the origin of the illness is impossible to establish. Foreign researchers have demonstrated a correlation between Helicobacter pylori (HP) persistence and such conditions as chronic relapsing urticaria (CRLU), Quincke's edema (QO) and respiratory manifestations of allergy (usually bronchial asthma (BA)). HP may participate in the forming of ADs in three possible ways: 1) the bacteria interact with mast cells, and thus are able to initiate mediator liberation; 2) being full antigens, the bacteria themselves are able to cause allergy; 3) the infection process development impairs the barrier function of the alimentary tract mucosa, thus impairing food processing. This creates conditions for allergic food particles to enter bloodstream, which is facilitated by inflammatory lesions of the intestinal tract, protozoal and helminthic invasion, and dysbacteriosis. The aim of the study was to determine how frequently patients with CRU, QO and BA have HP invasion and develop intestinal microflora disbalance, as well as to find out whether there is a correlation between HP infection and alterations in the IgE-system, and establish anti-HP therapy effects, measuring the levels of anti-helicobacter antibody and IgE before and after the treatment. The study revealed HP invasion in 89.2% of patients with chronic ADs; 96.7% of the subjects had disturbances of microbiocenosis; total IgE level correlated with the allergic process activity and anti-helicobacter antibody level; eradicational therapy was more effective when included proton pump inhibitor, clarithromycin and flemoxin than when de-nol, clarithromycin and flemoxin were administered. According to the results of the study, anti-helicobacter therapy allows more effective treatment of patients with relapsing ADs and HP infection.
Karel'skaia
I A
IA
Ignat'ev
V K
VK
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood; D001249:Asthma / Q000097:blood / Q000150:complications* / Q000276:immunology; D002908:Chronic Disease; D017291:Clarithromycin / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005243:Feces / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D016480:Helicobacter pylori / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D016896:Treatment Outcome; D014581:Urticaria / Q000097:blood / Q000150:complications* / Q000276:immunology
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D004791:Enzyme Inhibitors; D007073:Immunoglobulin E; D017291:Clarithromycin; D009853:Omeprazole